Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

被引：0
|
作者：
Mamounas, E
Tang, G
Bryant, J
Paik, S
Shak, S
Costantino, J
Watson, D
Wickerham, DL
Wolmark, N
机构：
[1] NSABP, Pittsburgh, PA USA
[2] Aultman Hlth Fdn, Canton, OH USA
[3] Genom Hlth Inc, Redwood City, CA USA
[4] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S16 / S16
页数：1
相关论文
共 50 条
  • [41] Impact of the 21-gene assay on treatment decisions in high-risk patients with ER-positive HER2-negative early breast cancer: Results of the KARMA Dx study
    Llombart, A.
    Andres, R.
    Anton Torres, A.
    Martinez, N.
    Rodriguez, C.
    Sanchez-Rovira, P.
    Rojas, B.
    Ruiz Borrego, M.
    Bermejo, B.
    Martinez de Duenas, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Chemotherapy (CT) decision in node-positive (N plus ), ER plus , early breast cancer (EBC) after new ASCO Guideline - evidence for the 21-gene Recurrence Score (RS) assay
    Mamounas, E. P.
    Goldstein, L. J.
    Penault-Llorca, F.
    Roche, H.
    Gluz, O.
    Harbeck, N.
    Nitz, U.
    O'shaughnessy, J.
    Albain, K. S.
    BREAST, 2017, 32 : S98 - S98
  • [43] Application of 21-gene recurrence score in patients with T1-2, N0-1 ER-positive/HER2 negative breast cancer: Survival analysis in relation to clinical risk score
    Bae, Soong June
    Ahn, Sung Gwe
    Park, Soeun
    Cha, Chi Hwan
    Kim, Dooreh
    Lee, Janghee
    Jeong, Joon
    CANCER RESEARCH, 2020, 80 (04)
  • [44] Development of recurrence risk score using 95-gene classifier and its application to formalin-fixed paraffin-embedded tissues in ER-positive, HER2-negative and node-negative breast cancer
    Naoi, Yasuto
    Saito, Yuria
    Kishi, Kazuki
    Shimoda, Masafumi
    Kagara, Naofumi
    Miyake, Tomohiro
    Tanei, Tomonori
    Shimazu, Kenzo
    Kim, Seung Jin
    Noguchi, Shinzaburo
    ONCOLOGY REPORTS, 2019, 42 (06) : 2680 - 2685
  • [45] Lack of concordance between Ki67 labeling index and 21-gene Breast Recurrence Score® test results in patients with ER+, HER2-, clinically node-negative breast cancer: a secondary analysis of TransNEOS neoadjuvant study
    Narui, K.
    Masuda, N.
    Yamamoto, Y.
    Fujisawa, T.
    Toyama, T.
    Kashiwaba, M.
    Sakai, T.
    Shibahara, Y.
    Sasano, H.
    Iwata, H.
    BREAST, 2019, 44 : S97 - S97
  • [46] META-ANALYSIS OF PROSPECTIVE EUROPEAN STUDIES ASSESSING THE IMPACT OF USING THE 21-GENE RECURRENCE SCORE ASSAY ON CLINICAL DECISION MAKING IN WOMEN WITH ER-POSITIVE, HER2-NEGATIVE EARLY STAGE BREAST CANCER
    Albanell, J.
    Holt, S.
    Gligorov, J.
    Eiermann, W.
    Svedman, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 97 - 97
  • [47] 21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer
    Zhang, Wen-Wen
    Tong, Qin
    Sun, Jia-Yuan
    Hua, Xin
    Long, Zhi-Qing
    Deng, Jia-Peng
    Dong, Yong
    Li, Fang-Yan
    He, Zhen-Yu
    Wu, San-Gang
    Lin, Huan-Xin
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [48] A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Oncotype DX) in estrogen receptor positive (ER plus ) node negative (pN0) breast cancer in academic Canadian centers
    Davidson, James Ashley
    Cromwell, Ian
    Ellard, Susan
    Lohrisch, Caroline A.
    Gelmon, Karen A.
    Shenkier, Tamara Nina
    Villa, Diego
    Lim, Howard John
    Sun, Sophie
    Taylor, Sara Kristina
    Taylor, Marianne
    Czerkawski, Barbara
    Hayes, Malcolm
    Ionescu, Diana
    Pope, Janice
    Berube, Jayne
    Yoshizawa, Carl N.
    Chao, Calvin
    Peacock, Stuart
    Chia, Stephen K. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Use of Adjuvant Chemoendocrine Therapy vs Adjuvant Endocrine Therapy in Node-Negative Early-Stage Breast Cancer Patients Stratified as Midrange Risk by 21-Gene Oncotype DX Breast Recurrence Score Assay: A MetaAnalysis Study
    Gonong, Patrick Adrian G.
    Torillo, Maila Rose L.
    Lao, Linelle Stacy T.
    Soliven, Albert U.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2019, 229 (04) : S41 - S42
  • [50] A prospective clinical utility study of the impact of the 21-gene recurrence score (RS) assay in the treatment of estrogen receptor positive (ER+), HER2 negative (HER2-), 1-3 node positive (N plus ) breast cancer (BC)
    Sun, Julia
    Fenton, Dave
    Baxter, Simon
    Chan, Angela
    Roberts, Sara
    Feng, Xiaolan
    Lohrisch, Caroline
    Gelmon, Karen
    Shenkier, Tamara
    Chia, Stephen
    CANCER RESEARCH, 2018, 78 (04)
12345